HATSUE FUJINO

Last Updated :2025/07/14

Affiliations, Positions
Hiroshima University Hospital, Assistant Professor
E-mail
fujino920hiroshima-u.ac.jp
Other Contact Details
1-2-3Kasumi, Minami-ku, Hiroshima, Japan
TEL : (+81)82-257-5555 FAX : (+81)
Self-introduction
Expertise: Chronic Viral Hepatitis, Cirrhosis, Fatty Liver, Gastroenterology, Liver Disease, Liver Test Abnormalities

Basic Information

Major Professional Backgrounds

  • 2007/04, 2009/03, JA ONOMICHI GENERAL HOSPITAL
  • 2009/04, 2012/03, Chugoku Rosai Hospital, Clinical Fellow
  • 2012/04/01, 2013/03/31, Hiroshima University, Hospital, Clinical Fellow
  • 2014/04, 2015/03, Toranomon Hospital, Clinical Fellow
  • 2017/04/01, 2017/09/30, Hiroshima University, Hospital, Clinical Fellow
  • 2017/10/01, Hiroshima University, Hospital, Assistant Professor

Educational Backgrounds

  • Hiroshima University, Faculty of Medicine, Japan, 2001/04, 2007/03
  • Hiroshima University, Graduate School of Biomedical & Health Sciences , Japan, 2013/04, 2017/03

Academic Degrees

  • Hiroshima University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical internal medicine;Gastroenterology

Research Keywords

  • Hepatitis virus
  • Cirrhosis

Affiliated Academic Societies

  • The Japanese Society of Internal Medicine
  • The Japanese Society of Gastroenterology
  • The Japan Gastroenterological Endoscopy Society
  • The Japan Society of Hepatology

Educational Activity

Course in Charge

  1. 2025, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2025, Undergraduate Education, Intensive, Introduction to clinical clerkship
  3. 2025, Undergraduate Education, Intensive, Practice of Medicine I
  4. 2025, Undergraduate Education, Intensive, Practice of Medicine II
  5. 2025, Undergraduate Education, First Semester, Internal Medicine I

Research Activities

Academic Papers

  1. Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution, DEN OPEN, 5(1), 202504
    Link to Paper Search Results by DOI
  2. ★, Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B, JOURNAL OF GASTROENTEROLOGY, 60(4), 469-478, 202504
    Link to Paper Search Results by DOI
  3. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY, 60(3), 328-339, 202503
    Link to Paper Search Results by DOI
  4. Multiomics Analysis of Liver Molecular Dysregulation Leading to Nonviral-Related Hepatocellular Carcinoma Development, JOURNAL OF PROTEOME RESEARCH, 24(3), 1102-1117, 20250221
    Link to Paper Search Results by DOI
  5. Impact of viral eradication by direct-acting antivirals on clinical outcomes after curative treatment for hepatitis C virus-associated hepatocellular carcinoma, THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 18, 2025
    Link to Paper Search Results by DOI
  6. A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine, CLINICAL JOURNAL OF GASTROENTEROLOGY, 18(1), 107-113, 202502
    Link to Paper Search Results by DOI
  7. Prediction of Hepatocellular Carcinoma After Hepatitis C Virus Sustained Virologic Response Using a Random Survival Forest Model, JCO CLINICAL CANCER INFORMATICS, 8, 202412
    Link to Paper Search Results by DOI
  8. Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma, HEPATOLOGY RESEARCH, 55(1), 149-154, 202501
    Link to Paper Search Results by DOI
  9. Alteration of Gene Expression After Entecavir and Pegylated Interferon Therapy in HBV-Infected Chimeric Mouse Liver, VIRUSES-BASEL, 16(11), 202411
    Link to Paper Search Results by DOI
  10. ★, Value of autotaxin for hepatocellular carcinoma risk assessment in chronic hepatitis B patients treated with nucleos(t)ide analogs, HEPATOLOGY RESEARCH, 54(11), 981-992, 202411
    Link to Paper Search Results by DOI
  11. ★, The Hepatitis B Virus PreS1/HBsAg Ratio Is a Predictive Marker for the Occurrence of Hepatocellular Carcinoma, LIVERS, 4(3), 364-376, 202409
    Link to Paper Search Results by DOI
  12. Useful Predictor for Exacerbation of Esophagogastric Varices after Hepatitis C Virus Eradication by Direct-Acting Antivirals, LIVERS, 4(3), 352-363, 202409
    Link to Paper Search Results by DOI
  13. Real-world efficacy and safety of durvalumab-tremelimumab as second-line systemic therapy after atezolizumab-bevacizumab in unresectable hepatocellular carcinoma, MEDICINE, 103(34), 20240823
    Link to Paper Search Results by DOI
  14. Impact of MAFLD criteria on postoperative recurrence of non-B, non-C HCC, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 36(4), 430-437, 202404
    Link to Paper Search Results by DOI
  15. Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma, CANCERS, 16(7), 202404
    Link to Paper Search Results by DOI
  16. The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib, ONCOLOGY, 101(8), 491-501, 202308
    Link to Paper Search Results by DOI
  17. Efficacy and safety of atezolizumab plus bevacizumab in patients with portal hypertension for unresectable hepatocellular carcinoma, CANCER MEDICINE, 13(5), 202403
    Link to Paper Search Results by DOI
  18. Clinical Outcomes of Switching from Zoledronic Acid to Denosumab for the Management of Severe Bone Metastasis from Hepatocellular Carcinoma: A Single-Center, Open-Label, Prospective Intervention Trial, YONAGO ACTA MEDICA, 66(4), 422-431, 202311
    Link to Paper Search Results by DOI
  19. Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma, CANCERS, 15(22), 202311
    Link to Paper Search Results by DOI
  20. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma, COMMUNICATIONS MEDICINE, 3(1), 20231025
    Link to Paper Search Results by DOI
  21. Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma., LIVER CANCER, 12(3), 251-261, 202308
    Link to Paper Search Results by DOI
  22. Serum interleukin-6 level predicts the prognosis for patients with alcohol-related acute-on-chronic liver failure, HEPATOLOGY INTERNATIONAL, 17(5), 1225-1232, 202310
    Link to Paper Search Results by DOI
  23. Correlation between serum pro-inflammatory cytokine levels and the prognosis of the patients with acute liver failure, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 38(9), 1637-1646, 202309
    Link to Paper Search Results by DOI
  24. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment, CANCERS, 15(17), 202309
    Link to Paper Search Results by DOI
  25. Sodium-glucose cotransporter-2 inhibitors improve FibroScan-aspartate aminotransferase scores in patients with nonalcoholic fatty liver disease complicated by type 2 diabetes, EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 35(9), 989-996, 202309
    Link to Paper Search Results by DOI
  26. Successful Lenvatinib Re-challenge following Atezolizumab Plus Bevacizumab Combination Therapy Failure for Unresectable Hepatocellular Carcinoma, INTERNAL MEDICINE, 62(12), 1771-1774, 2023
    Link to Paper Search Results by DOI
  27. Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study, BMC GASTROENTEROLOGY, 23(1), 20230628
    Link to Paper Search Results by DOI
  28. Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein, CANCERS, 15(8), 202304
    Link to Paper Search Results by DOI
  29. Hepatitis B Virus (HBV) Upregulates TRAIL-R3 Expression in Hepatocytes Resulting in Escape From Both Cell Apoptosis and Suppression of HBV Replication by TRAIL, JOURNAL OF INFECTIOUS DISEASES, 227(5), 686-695, 20230301
    Link to Paper Search Results by DOI
  30. Effectiveness of Repeated Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma-Consideration of the Locations of Target Lesions, CANCERS, 15(3), 202302
    Link to Paper Search Results by DOI
  31. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography, JOURNAL OF MEDICAL ULTRASONICS, 50(1), 57-62, 202301
    Link to Paper Search Results by DOI
  32. Hepatic venous pressure gradient after balloon-occluded retrograde transvenous obliteration and liver stiffness measurement predict the prognosis of patients with gastric varices, BMC GASTROENTEROLOGY, 22(1), 20221222
    Link to Paper Search Results by DOI
  33. The presence of vessels encapsulating tumor clusters is associated with an immunosuppressive tumor microenvironment in hepatocellular carcinoma, INTERNATIONAL JOURNAL OF CANCER, 151(12), 2278-2290, 20221215
    Link to Paper Search Results by DOI
  34. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis, JOURNAL OF MEDICAL ULTRASONICS, 49(3), 443-450, 202207
    Link to Paper Search Results by DOI
  35. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection, JOURNAL OF GASTROENTEROLOGY, 57(9), 676-683, 202209
    Link to Paper Search Results by DOI
  36. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection., J Gastroenterol, 2022
  37. The effect of the skin-liver capsule distance on the accuracy of ultrasound diagnosis for liver steatosis and fibrosis., J Med Ultrason, 2022
  38. HBV upregulates TRAIL-R3 expression in hepatocytes for escaping both cell apoptosis and suppression of their replication by TRAIL., J Infect Dis, 2022
  39. Pathological Complete Response to Lenvatinib after Failure of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma., Liver Cancer, 2021
  40. A second attack of cholestasis associated with erythropoietic protoporphyria was successfully treated by plasma exchange and blood transfusion., Clin J Gastroenterol, 7(4), 333-337, 2014
  41. The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment, PLOS ONE, 17(1), 20220118
    Link to Paper Search Results by DOI
  42. Construction of an anti-hepatitis B virus preS1 antibody and usefulness of preS1 measurement for chronic hepatitis B patients Anti-HBV PreS1 antibody, JOURNAL OF INFECTION, 84(3), 391-399, 202203
    Link to Paper Search Results by DOI
  43. Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene, CASE REPORTS IN GASTROENTEROLOGY, 16(1), 110-115, 2022
    Link to Paper Search Results by DOI
  44. Underestimation of impaired glucose tolerance and usefulness of a continuous glucose monitoring system in chronic liver disease, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 37(3), 592-599, 202203
    Link to Paper Search Results by DOI
  45. ★, Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 45(6), 607-617, 2015
    Link to Paper Search Results by DOI
  46. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48(4), 264-274, 2018
    Link to Paper Search Results by DOI
  47. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53(1), 107-118, 2018
    Link to Paper Search Results by DOI
  48. ★, Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49(12), 1548-1556, 2014
    Link to Paper Search Results by DOI
  49. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12(8), 2017
    Link to Paper Search Results by DOI
  50. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, Antiviral Therapy, 23(3), 239-248, 2018
    Link to Paper Search Results by DOI
  51. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52(3), 366-375, 2017
    Link to Paper Search Results by DOI
  52. Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46(12), 1256-1263, 2016
    Link to Paper Search Results by DOI
  53. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46(9), 944-948, 2016
    Link to Paper Search Results by DOI
  54. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31(5), 1009-1015, 2016
    Link to Paper Search Results by DOI
  55. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 25(11), 3272-3281, 2015
    Link to Paper Search Results by DOI
  56. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 45(6), 656-662, 201506
    Link to Paper Search Results by DOI
  57. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report, HEPATOLOGY RESEARCH, 45(6), 705-710, 201506
    Link to Paper Search Results by DOI
  58. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30(4), 726-732, 201504
    Link to Paper Search Results by DOI
  59. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 44(14), E420-E427, 201412
    Link to Paper Search Results by DOI
  60. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44(14), E447-E454, 201412
    Link to Paper Search Results by DOI
  61. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib, HEPATOLOGY RESEARCH, 44(13), 1320-1328, 201412
    Link to Paper Search Results by DOI
  62. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients, HEPATOLOGY RESEARCH, 44(7), 740-749, 201407
    Link to Paper Search Results by DOI
  63. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29(5), 1035-1042, 201405
    Link to Paper Search Results by DOI
  64. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 61(130), 323-328, 2014
  65. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28(12), 1834-1841, 201312
    Link to Paper Search Results by DOI
  66. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C, JOURNAL OF MEDICAL VIROLOGY, 90(12), 1834-1840, 201812
    Link to Paper Search Results by DOI
  67. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25(12), 1555-1564, 201812
    Link to Paper Search Results by DOI
  68. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48(13), 1118-1130, 201812
    Link to Paper Search Results by DOI
  69. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91(4), 650-658, 201904
    Link to Paper Search Results by DOI
  70. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54(3), 291-296, 201903
    Link to Paper Search Results by DOI
  71. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3(3), 348-355, 201903
    Link to Paper Search Results by DOI
  72. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54(7), 650-659, 201907
    Link to Paper Search Results by DOI
  73. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100(7), 1123-1131, 201907
    Link to Paper Search Results by DOI
  74. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12(4), 341-346, 201908
    Link to Paper Search Results by DOI
  75. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19(1), 20191024
    Link to Paper Search Results by DOI
  76. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 55(2), 217-226, 2020
    Link to Paper Search Results by DOI
  77. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124, 2020
    Link to Paper Search Results by DOI
  78. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(2), 267-270, 202004
    Link to Paper Search Results by DOI
  79. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12, 202005
    Link to Paper Search Results by DOI
  80. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50(7), 885-888, 202007
    Link to Paper Search Results by DOI
  81. Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy cases, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 35(8), 1412-1419, 202008
    Link to Paper Search Results by DOI
  82. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11, 202005
  83. Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy., J Med Virol., 92(2), 210-218, 202002
  84. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk., Clin J Gastroenterol.
  85. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13(5), 867-872, 202010
    Link to Paper Search Results by DOI
  86. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50(11), 1222-1233, 202011
    Link to Paper Search Results by DOI
  87. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 98(11), 787-797, 202011
    Link to Paper Search Results by DOI
  88. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50(11), 1234-1243, 202011
    Link to Paper Search Results by DOI
  89. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28(2), 400-409, 2021
    Link to Paper Search Results by DOI
  90. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222(12), 2061-2070, 20201215
    Link to Paper Search Results by DOI
  91. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(1), 283-287, 2021
    Link to Paper Search Results by DOI
  92. Clinical Usefulness of Serum Autotaxin for Early Prediction of Relapse in Male Patients with Type 1 Autoimmune Pancreatitis, DIGESTIVE DISEASES AND SCIENCES, 66(4), 1268-1275, 202104
    Link to Paper Search Results by DOI
  93. Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures, INTERNAL MEDICINE, 60(6), 829-837, 2021
    Link to Paper Search Results by DOI
  94. A case of acute liver failure with echovirus infection diagnosed by a multi-virus real-time PCR system, IDCASES, 23, 2021
    Link to Paper Search Results by DOI
  95. Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy, ONCOLOGY, 99(5), 327-335, 202104
    Link to Paper Search Results by DOI
  96. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 559, 78-83, 20210625
    Link to Paper Search Results by DOI
  97. In vitro analysis of hepatic stellate cell activation influenced by transmembrane 6 superfamily 2 polymorphism, MOLECULAR MEDICINE REPORTS, 23(1), 202101
    Link to Paper Search Results by DOI
  98. Extracellular water to total body water ratio obtained by bioelectrical impedance analysis determines the dose intensity of lenvatinib for the treatment of patients with advanced hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 36(6), 1685-1693, 202106
    Link to Paper Search Results by DOI
  99. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib, JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 40(1), 20210626
    Link to Paper Search Results by DOI
  100. Therapeutic effects of sleeve gastrectomy for non-alcoholic steatohepatitis estimated by paired liver biopsy in morbidly obese Japanese patients, MEDICINE, 100(26), 20210702
    Link to Paper Search Results by DOI
  101. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib, INTERNAL MEDICINE, 60(13), 2047-2053, 2021
    Link to Paper Search Results by DOI
  102. Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma, ONCOLOGY, 99(8), 507-517, 2021
    Link to Paper Search Results by DOI
  103. Clinical Outcomes of 2nd-and 3rd-Line Regorafenib for Advanced Hepatocellular Carcinoma, ONCOLOGY, 99(8), 491-498, 202107
    Link to Paper Search Results by DOI
  104. Increasing incidence of non-HBV- and non-HCV-related hepatocellular carcinoma: single-institution 20-year study, BMC GASTROENTEROLOGY, 21(1), 20210731
    Link to Paper Search Results by DOI
  105. Serum PreS1 and HBsAg ratio reflects liver fibrosis and predicts the development of hepatocellular carcinoma in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 28(9), 1304-1311, 202109
    Link to Paper Search Results by DOI
  106. Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice, CANCERS, 13(16), 202108
    Link to Paper Search Results by DOI
  107. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab, MEDICINE, 100(42), 20211022
    Link to Paper Search Results by DOI
  108. Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma, CANCERS, 14(2), 202201
    Link to Paper Search Results by DOI

Invited Lecture, Oral Presentation, Poster Presentation

  1. Study of infectivity in various genotypes of hepatitis B virus, Hatsue Fujino, Kenji Yamaoka, Yasutoshi Fujii, Atsushi Ono, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, C. Nelson Hayes, Masataka Tsuge, Shiro Oka, 2024 International HBV Meeting, 2024/09/11, Without Invitation, English, Chicago, United States
  2. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mouse to HepG2/NTCP cells, Hatsue Fujino, Maiko Namba, Yasutoshi Fujii, Shinsuke Uchikawa, Yuji Teraoka, Takuro Uchida, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Tomokazu Kawaoka, Daiki Miki, C. Nelson Hayes, Michio Imamura and Hiroshi Aikata, The Liver Meeting 2022 AASLD, 2022/11/22, Without Invitation, English, AASLD, Washington DC
  3. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mice to HepG2/NTCP cells, Hatsue Fujino, Michio Imamura, Hiroshi Aikata, 2022/06/02, Without Invitation, English
  4. Serum autotaxin levels is useful to evaluate fibrosis during entecavir therapy and to predict the development of hepatocellular carcinoma in patients with chronic Hepatitis B., Hatsue Fujino, Kei Morio, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Hayes Clair Nelson, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, International HBV Meeting, 2019, Without Invitation, English, Melbourne
  5. Investigation of infectivity of serum-derived HBV from patients and human hepatocyte chimeric mouse to HepG2/NTCP cells., Hatsue Fujino, Maiko Namba, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Tomokazu Kawaoka, Daiki Miki, Masataka Tsuge, Hiromi Abe-Chayama, Hayes Clair Nelson, Michio Imamura, Hiroshi Aikata, Kazuaki Chayama, International HBV Meeting, 2019, Without Invitation, English, Melbourne
  6. Serum Autotaxin Levels Reflect Improvement of Liver Fibrosis in Patients with Chronic Hepatitis B during Entecavir Treatment., Fujino H., Chayama K., AASLD The liver meeting 2018, 2018/11/13, Without Invitation, English, American Association for the study of liver disease, San Francisco
  7. Hepatitis B Core-Related Antigen (HBcrAg) Is a Novel Risk Marker for Hepatocellular Carcinoma during Nucleoside Analoge Treatment., Fujino H., Chayama K., AASLD The liver meeting 2018, 2018/11/13, Without Invitation, English, American Association of the study of liver disease, San Francisco

Awards

  1. 2019, Travel grant award, International HBV Meeting

External Funds

Acceptance Results of Competitive Funds

  1. Research Program on Hepatitis, 2023//4//1, 2024//3//3
  2. Research Program on Hepatitis, 2022//0/4/, 2023//0/3/
  3. Research Program on Hepatitis, 2023/04/01, 2024/03/31
  4. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2021, 2024
  5. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2023, 2024
  6. Research Program on Hepatitis, 2021/04/01, 2022/03/31